HOUSTON -- The tumor-derived vaccine vitespen (Oncophage) does not prevent kidney cancer recurrence or improve survival despite promising early results, researchers said.
Vaccine Therapy Disappoints for Kidney CancerCourtesy MedPage Today Infectious Disease Thu, 07/03/2008 - 17:30
HOUSTON -- The tumor-derived vaccine vitespen (Oncophage) does not prevent kidney cancer recurrence or improve survival despite promising early results, researchers said. Sponsors
Related itemsPlasma DNA level is a reliable marker of recurrent esophageal ca...
Weizmann Institute scientists' new technique gets to the root of...
Stanford researchers find molecule that kills kidney cancer cell...
Patient Web sites used for news, support in crisis
Patient Web sites used for news, support in crisis
|
Popular by tags WeekMonth |
Post new comment